drugset / Trial / NCT07052903
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
Timeline
- Start
- 2025-07-02
- Primary completion
- 2030-05-28
- Completion
- 2032-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nucresiran | Unknown | 300 mg | Subcutaneous |
Indications
No indication recorded.